Enanta Pharmaceuticals

Yahoo Finance • 15 hours ago

Enanta's Oral Antiviral Shows Key Benefit For High-Risk Adults With RSV In Phase 2b Trial; Stock Up

(RTTNews) - Enanta Pharmaceuticals Inc. (ENTA) has reported topline data from its RSVHR study of Zelicapavir, demonstrating a clinically meaningful benefit in high-risk adults infected with RSV. RSVHR is a phase 2b placebo-controlled stud... Full story

Yahoo Finance • 21 hours ago

Biggest stock movers Monday: GSK, MLTX, and more

[Abstract Finance Technology Concept] koto_feja Stock futures were higher Monday morning while Treasury yields slipped as investors awaited September’s upcoming nonfarm payrolls report, hoping for clarity on U.S. labor market health, whil... Full story

Yahoo Finance • 3 days ago

Enanta in focus ahead of mid-stage trial data for RSV antiviral

[RSV, respiratory syncytial virus, human orthopneumovirus, contagious child disease] BeritK/iStock via Getty Images * Enanta Pharmaceuticals (NASDAQ:ENTA [https://seekingalpha.com/symbol/ENTA]) has set up a conference call for Monday at... Full story

Yahoo Finance • 3 days ago

Enanta Pharma To Report Respiratory Syncytial Virus Trial Results On Sep.29

(RTTNews) - Enanta Pharmaceuticals Inc. (ENTA) will hold a conference call and webcast on Monday, September 29, 2025, at 8:30 a.m. ET to share topline results from its RSVHR study. RSVHR is a phase 2b trial evaluating its lead drug candid... Full story

Yahoo Finance • last month

Pfizer sued by Enanta in EU over patent infringement related to COVID pill

Alexander Sikov/iStock via Getty Images Enanta Pharmaceuticals (NASDAQ:ENTA [https://seekingalpha.com/symbol/ENTA]) announced on Wednesday a lawsuit filed in the EU against Pfizer (NYSE:PFE [https://seekingalpha.com/symbol/PFE]) and some... Full story

Yahoo Finance • last month

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

WATERTOWN, Mass., August 20, 2025--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, anno... Full story

Yahoo Finance • 2 months ago

Entain lifts FY guidance as H1 EBITDA rises 11% on online, BetMGM growth

Investing.com -- Entain plc on Tuesday lifted its full-year profit guidance after posting an 11% rise in first-half underlying EBITDA to £583 million, driven by strong online growth and a 35% revenue surge at U.S. joint venture BetMGM. To... Full story

Yahoo Finance • 3 months ago

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine's DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed a Letter of Intent (LOI) with DoveTree LLC, founded by Harvard University Prof... Full story

Yahoo Finance • 4 months ago

Enanta Pharmaceuticals' SWOT analysis: stock shifts focus to immunology amid RSV progress

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a biotechnology company specializing in small molecule drugs for viral infections and liver diseases, is undergoing a strategic shift towards immunology while maintaining its focus on respiratory... Full story

Yahoo Finance • 4 months ago

AbbVie Secures FDA Approval to Expand Mavyret’s Label

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals... Full story

Yahoo Finance • 4 months ago

FDA Expands AbbVie's Mavyret Label To Include Pediatric Patients With Hepatitis C Infection

The U.S. Food and Drug Administration (FDA) approved a label expansion for AbbVie Inc’s (NYSE:ABBV) Mavyret (glecaprevir/pibrentasvir), an oral pangenotypic direct-acting antiviral (DAA) therapy. It is now approved for adults and pediatri... Full story

Yahoo Finance • 5 months ago

Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts

We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against other best breakout stocks to buy accordi... Full story

Yahoo Finance • last year

Enanta Pharmaceuticals, Inc. (ENTA): Caligan Partners’ Top Holding Right Now?

We recently compiled a list of the Top 10 Holdings of Caligan Partners.In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against Caligan Partners' other top holdings. Founded in 2017,... Full story

Yahoo Finance • 2 years ago

Insider Sell Alert: Director Terry Vance Sells 15,295 Shares of Enanta Pharmaceuticals Inc (ENTA)

In a notable insider transaction, Director Terry Vance has parted with 15,295 shares of Enanta Pharmaceuticals Inc (NASDAQ:ENTA), a significant move that warrants a closer look by investors and market analysts. The sale, which took place o... Full story

Yahoo Finance • 2 years ago

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

WATERTOWN, Mass., November 22, 2023--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on treatments for viral infections, today... Full story

Yahoo Finance • 3 years ago

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference

Progresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023 Presents New Preclinical In Vivo Data Demonstrating EDP-235’s Efficacy and Prevention of COVID-19 Transmission Expands... Full story

Yahoo Finance • 3 years ago

Enanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022

WATERTOWN, Mass., October 19, 2022--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced ne... Full story

Yahoo Finance • 3 years ago

New Preclinical Data for EDP-235, Enanta’s Oral Coronavirus Protease Inhibitor Designed for the Treatment of COVID-19, to be Presented at IDWeek™ 2022

WATERTOWN, Mass., September 07, 2022--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced t... Full story

Yahoo Finance • 3 years ago

Enanta Pharmaceuticals (ENTA) Q3 2022 Earnings Call Transcript

On the call today are Dr. Jay Luly, president and chief executive officer; Paul Mellett, our chief financial officer; and other members of Enanta's senior management team. Thank you, Jennifer, and good afternoon, everyone.... Full story

Yahoo Finance • 3 years ago

Enanta Pharmaceuticals Announces Positive Data from a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

– 200mg and 400mg Once-Daily Doses Achieved Strong Exposure Multiples Over EC90 and Were Generally Safe and Well-Tolerated – Plan to Initiate Phase 2 Study in 4Q 2022 WATERTOWN, Mass., July 29, 2022--(BUSINESS WIRE)--Enanta Pharmaceutica... Full story